New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
08:02 EDTSQNM, DGXSequenom and Quest Diagnostics announce collaboration agreement
Sequenom (SQNM) and Quest Diagnostics (DGX) announced an agreement under which Quest will offer national access to Sequenom Laboratories' MaterniT21 PLUS laboratory-developed test. Using a maternal blood sample, the noninvasive prenatal test analyzes chromosomal material in cell-free fetal DNA of pregnant women at increased risk for fetal chromosomal abnormalities. Quest expects to begin offering access to the test in the third quarter. In addition, Quest has formed a license agreement with Sequenom for certain NIPT patents and patent applications. The license agreement is the first formed by Sequenom with a commercial lab in the United States. Quest intends to use the intellectual property for the purposes of developing and validating its own proprietary lab-developed NIPT test. Quest expects to introduce this new offering in 2015. Additional terms of the agreement were not disclosed.
News For SQNM;DGX From The Last 14 Days
Check below for free stories on SQNM;DGX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 24, 2014
07:05 EDTDGXQuest Diagnostics narrows 2014 adjusted EPS view to $4.00-$4.10 from $3.95-$4.15
Subscribe for More Information
07:02 EDTDGXQuest Diagnostics reports Q2 adjusted EPS $1.08, consensus $1.06
Subscribe for More Information
July 22, 2014
07:08 EDTDGXLife Sciences highlights this week at Canaccord
Canaccord highlighted six diagnostic names that report this week and recommends buying Top Pick IDEXX (IDXX) into the print given strong recurring razor/razorblade sales and consistent organic growth. The analyst expects Hold rated Quest Diagnostics (DGX) to report upside to Street estimates of $1.06/$1.882B, Quidel (QDEL) to have an uneventful report, Exact Sciences (EXAS) to provide an update on numerous catalysts near-term and Abaxis (ABAX) to report earnings below consensus. Lastly, the firm is cautious on Meridian Bioscience (VIVO) following a competitor report last week.
July 21, 2014
11:21 EDTSQNMSequenom VisibiliT launch unlikely to have near-term impact, says Ladenburg
Subscribe for More Information
07:02 EDTSQNMSequenom subsidiary launched VisibiliT test in international markets
Sequenom announced that its wholly owned subsidiary, Sequenom Laboratories, will soon launch the VisibiliT laboratory-developed test in international markets. The VisibiliT test utilizes maternal age, fetal fraction and the relative amount of chromosomal material for chromosomes 21 and 18 to generate a highly accurate, personalized risk score.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use